Companies Dominating the Medication-assisted Treatment Landscape
- Indivior PLC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Mallinckrodt Pharmaceuticals
- Titan Pharmaceuticals, Inc.
- Alkermes plc
- Orexo AB
- Mylan N.V.
- Teva Pharmaceuticals Industries Ltd.
- Lupin limited
- Hikma Pharmaceuticals PLC
- Novartis AG
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of medication-assisted treatment is assessed at USD 11.2 billion.
The medication-assisted treatment market size was valued at USD 10.42 billion in 2024 and is expected to reach USD 31.19 billion by 2037, expanding at around 8.8% CAGR during the forecast period i.e., between 2025-2037. Increase in substance abuse deaths, rising awareness of medication-assisted treatment and emergence of technological innovations will drive the market growth.
North America industry is likely to account for largest revenue share of 45% by 2037, impelled by surging funding by government for the MAT initiatives in the region
The major players in the market are Orexo AB, Novartis AG, Mylan N.V., Lupin Limited, Hikma Pharmaceuticals PLC and others.
